Rabeprazole

Identification

Summary

Rabeprazole is a proton pump inhibitor used to help gastrointestinal ulcers heal, to treat symptoms of gastroesophageal reflux disease (GERD), to eradicate Helicobacter pylori, and to treat hypersecretory conditions such as Zollinger-Ellison Syndrome.

Brand Names
Aciphex, Pariet
Generic Name
Rabeprazole
DrugBank Accession Number
DB01129
Background

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 359.443
Monoisotopic: 359.130362243
Chemical Formula
C18H21N3O3S
Synonyms
  • Clofezone
  • Rabeprazole
External IDs
  • LY-307640
  • LY307640

Pharmacology

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.

Mechanism of action

Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Humans
Absorption

Absolute bioavailability is approximately 52%.

Volume of distribution

Not Available

Protein binding

96.3% (bound to human plasma proteins)

Metabolism

Hepatic

Hover over products below to view reaction partners

Route of elimination

Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.

Half-life

1-2 hours (in plasma)

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
PathwayCategory
Rabeprazole Metabolism PathwayDrug metabolism
Rabeprazole Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredIncreased gastric acid suppression.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredIncreased gastric acid suppression.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
AbataceptThe metabolism of Rabeprazole can be increased when combined with Abatacept.
AbemaciclibRabeprazole may decrease the excretion rate of Abemaciclib which could result in a higher serum level.
AbirateroneThe metabolism of Rabeprazole can be decreased when combined with Abiraterone.
AceclofenacAceclofenac may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Rabeprazole.
AcetaminophenAcetaminophen may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Take with or without food. Food delays drug absorption, but not to a clinically significant extent.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Rabeprazole sodium3L36P16U4R117976-90-6KRCQSTCYZUOBHN-UHFFFAOYSA-N
Product Images
International/Other Brands
Pariet
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AcipHexTablet, delayed release20 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-292014-12-31US flag
AcipHexTablet, delayed release20 mg/1Oralbryant ranch prepack1999-08-192006-09-30US flag63629 273320180907 15195 13i2djl
AcipHexTablet, delayed release20 mg/1OralCarilion Materials Management1999-08-19Not applicableUS flag68151 383420180907 15195 j5bsd5
AcipHexTablet, delayed release20 mg/1OralCardinal Health1999-08-192016-04-30US flag55154 245120180913 8702 v7pqav
AciphexTablet, delayed release20 mg/1OralPhysicians Total Care, Inc.2000-05-15Not applicableUS flag54868 418520180907 15195 16b0z58
AcipHexTablet, delayed release20 mg/1OralEisai Inc.1999-08-19Not applicableUS flag62856 0243 30 nlmimage10 bb39dd9e
AcipHex SprinkleCapsule, delayed release10 mg/1OralAytu Therapeutics, LLC2018-03-01Not applicableUS flag
AcipHex SprinkleGranule, delayed release10 mg/1OralEisai Inc.2013-03-262013-03-15US flag
AcipHex SprinkleCapsule, delayed release10 mg/1OralAvadel Pharmaceuticals (Usa), Inc.2014-10-012018-02-16US flag
AcipHex SprinkleCapsule, delayed release5 mg/1OralAytu Therapeutics, LLC2018-03-01Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Abbott-rabeprazoleTablet, delayed release20 mgOralBgp Pharma Ulc2014-07-212015-12-31Canada flag
Abbott-rabeprazoleTablet, delayed release10 mgOralBgp Pharma Ulc2014-10-172015-12-31Canada flag
AciphexTablet, delayed release20 mg/1OralAdvanced Rx Pharmacy of Tennessee, LLC2018-04-27Not applicableUS flag
AciphexTablet, delayed release20 mg/1OralAdvanced Rx Pharmacy of Tennessee, LLC2018-04-27Not applicableUS flag
Ag-rabeprazoleTablet, delayed release20 mgOralAngita Pharma Inc.Not applicableNot applicableCanada flag
Ag-rabeprazoleTablet, delayed release10 mgOralAngita Pharma Inc.Not applicableNot applicableCanada flag
Apo-rabeprazoleTablet, delayed release20 mgOralApotex Corporation2012-05-01Not applicableCanada flag
Apo-rabeprazoleTablet, delayed release10 mgOralApotex Corporation2012-05-01Not applicableCanada flag
Dom-rabeprazole ECTablet, delayed release10 mgOralDominion PharmacalNot applicableNot applicableCanada flag
Dom-rabeprazole ECTablet, delayed release20 mgOralDominion Pharmacal2012-09-26Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
RABEDIC 10/75 MG MR KAPSÜL, 20 ADETRabeprazole sodium (10 mg) + Diclofenac sodium (75 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABEDIC 10/75 MG MR KAPSÜL, 30 ADETRabeprazole sodium (10 mg) + Diclofenac sodium (75 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABEDIC 20/75 MG MR KAPSÜL, 20 ADETRabeprazole sodium (20 mg) + Diclofenac sodium (75 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABEDIC 20/75 MG MR KAPSÜL, 30 ADETRabeprazole sodium (20 mg) + Diclofenac sodium (75 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABEDIC MR 20/100 MG KAPSÜL, 20 ADETRabeprazole sodium (20 mg) + Diclofenac sodium (100 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABEDIC MR 20/100 MG KAPSÜL, 30 ADETRabeprazole sodium (20 mg) + Diclofenac sodium (100 mg)CapsuleOralTAKEDA İLAÇ SAĞLIK SAN. TİC. LTD. ŞTİ.2020-08-142017-12-06Turkey flag
RABELIS PLUS 20/10 MG KAPSUL, 30 ADETRabeprazole sodium (20 mg) + Domperidone maleate (10 mg)CapsuleOralVİTALİS İLAÇ SAN. TİC. A.Ş.2020-08-14Not applicableTurkey flag
RABELIS PLUS 20/30 MG MR KAPSUL, 30 ADETRabeprazole sodium (20 mg) + Domperidone maleate (30 mg)CapsuleOralVİTALİS İLAÇ SAN. TİC. A.Ş.2020-08-14Not applicableTurkey flag
RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞERabeprazole sodium (20 mg) + Sodium bicarbonate (1680 mg)Powder, for suspensionOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞERabeprazole sodium (20 mg) + Sodium bicarbonate (1680 mg)Powder, for suspensionOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
A02BD12 — Rabeprazole, amoxicillin and clarithromycinA02BD13 — Rabeprazole, amoxicillin and metronidazoleA02BC54 — Rabeprazole, combinationsM01AA05 — ClofezoneA02BC04 — RabeprazoleM02AA03 — Clofezone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidazole
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfoxide, pyridines, benzimidazoles (CHEBI:8768)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
32828355LL
CAS number
117976-89-3
InChI Key
YREYEVIYCVEVJK-UHFFFAOYSA-N
InChI
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
IUPAC Name
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1

References

Synthesis Reference

Sundaram Venkatraman, "Crystalline form Z of rabeprazole sodium and process for preparation thereof." U.S. Patent US20040180935, issued September 16, 2004.

US20040180935
General References
Not Available
Human Metabolome Database
HMDB0005026
KEGG Drug
D08463
KEGG Compound
C07864
PubChem Compound
5029
PubChem Substance
46506366
ChemSpider
4853
BindingDB
50070209
RxNav
114979
ChEBI
8768
ChEMBL
CHEMBL1219
Therapeutic Targets Database
DAP000727
PharmGKB
PA451216
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Rabeprazole
FDA label
Download (135 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticGastro-esophageal Reflux Disease (GERD)1
4CompletedOtherGastrointestinal Diseases2
4CompletedPreventionAdenocarcinoma, Tubular / Early Gastric Adenocarcinoma1
4CompletedPreventionNormal Subjects1
4CompletedTreatmentBacterial Infections / Helicobacter Infections1
4CompletedTreatmentGastric Ulcer1
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)3
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD) / Insomnia1
4CompletedTreatmentGastroesophageal Reflux2
4CompletedTreatmentGastroesophageal Reflux / Heartburn1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • Cardinal Health
  • Diversified Healthcare Services Inc.
  • DRX Pharmaceuticals
  • Eisai Inc.
  • Janssen-Ortho Inc.
  • Lake Erie Medical and Surgical Supply
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
Dosage Forms
FormRouteStrength
Tablet, delayed releaseOral20 mg/1
Capsule, delayed releaseOral5 mg/1
Granule, delayed releaseOral10 mg/1
Granule, delayed releaseOral5 mg/1
Tablet, extended releaseOral
Tablet, delayed releaseOral10 mg
Tablet, delayed releaseOral20 mg
Tablet, film coatedOral
CapsuleOral
Tablet, coatedOral10 mg
Tablet, delayed releaseOral
Capsule, delayed releaseOral10 mg/1
TabletOral
CapsuleOral
Powder, for suspensionOral
Prices
Unit descriptionCostUnit
Aciphex 20 mg Enteric Coated Tabs7.48USD tab
Aciphex ec 20 mg tablet6.08USD tablet
Aciphex 20 mg tablet ec5.9USD tablet
Pariet 20 mg Enteric-Coated Tablet1.46USD tablet
Apo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Novo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pms-Rabeprazole Ec 20 mg Enteric-Coated Tablet0.82USD tablet
Ran-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Sandoz Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pariet 10 mg Enteric-Coated Tablet0.73USD tablet
Apo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Novo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Pms-Rabeprazole Ec 10 mg Enteric-Coated Tablet0.41USD tablet
Ran-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Sandoz Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5045552No1991-09-032013-05-08US flag
CA2104531No1999-01-052013-08-20Canada flag
CA1336958No1995-09-122012-09-12Canada flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP2.04ALOGPS
logP2.09ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity98.07 m3·mol-1ChemAxon
Polarizability39.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6469
Caco-2 permeable+0.6664
P-glycoprotein substrateSubstrate0.6179
P-glycoprotein inhibitor IInhibitor0.5835
P-glycoprotein inhibitor IINon-inhibitor0.9387
Renal organic cation transporterInhibitor0.6194
CYP450 2C9 substrateNon-substrate0.8265
CYP450 2D6 substrateNon-substrate0.8623
CYP450 3A4 substrateSubstrate0.7174
CYP450 1A2 substrateInhibitor0.6677
CYP450 2C9 inhibitorNon-inhibitor0.7734
CYP450 2D6 inhibitorNon-inhibitor0.7875
CYP450 2C19 inhibitorInhibitor0.6661
CYP450 3A4 inhibitorNon-inhibitor0.6647
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7243
Ames testNon AMES toxic0.5726
CarcinogenicityNon-carcinogens0.8751
BiodegradationNot ready biodegradable0.939
Rat acute toxicity2.4215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5726
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Langtry HD, Markham A: Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs. 1999 Oct;58(4):725-42. [Article]
  2. Carswell CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs. 2001;61(15):2327-56. [Article]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [Article]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [Article]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
  3. Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T: In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70. [Article]
  4. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
Curator comments
Studies are limited to in vitro evidence.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18. [Article]
  2. Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD: Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30. [Article]
Details
5. Cytochrome P450 2C9
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
  2. Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD: Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD: Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [Article]

Drug created on June 13, 2005 13:24 / Updated on July 29, 2021 06:27